7b9625284b
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
- Source: inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md - Domain: health - Claims: 0, Entities: 2 - Enrichments: 1 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
996 B
996 B
Semaglutide + CBT for Cocaine Use Disorder (Phase 2)
Type: Clinical trial
Phase: 2
Status: Recruiting (as of May 2026)
Intervention: Semaglutide combined with cognitive behavioral therapy (CBT)
Population: Adults with diagnosed cocaine use disorder and BMI ≥25
Primary objective: Reduce cocaine cravings and use
Registry: withpower.com/trial/phase-2-cocaine-related-disorders-10-2025
Timeline
- 2025-10 — Trial opened for recruitment
- 2026-05 — Actively recruiting participants
Context
This trial follows the All of Us observational finding (Abegaz et al., March 2026) showing 75% lower odds of cocaine use disorder in GLP-1 users (OR=0.25). Cocaine use disorder has no FDA-approved pharmacotherapy, making this a high-priority unmet need. The trial combines semaglutide with CBT, reflecting the behavioral-biological integration model seen in other GLP-1 SUD trials.
Expected Results
Phase 2 results anticipated 2027-2028.